Skip to main content

Table 3 Primary, isolated conjunctival lymphoma: Outcome, recurrence, and side effects of local treatment

From: Classification, diagnosis, and management of conjunctival lymphoma

Therapy type

Author

Year of publication

Number of eyes

Laterality

Histologic subtype or tumor grade

Response rate (CR + PR)

Follow up (months)

Local recurrence rate

Side effects

Radiotherapy

Baldini et al. [53]

1998

5

Unilateral

EMZL (100%)

100%

76 (median)

0%

Cataract (1 patient)

Bhatia et al. [54]

2002

17

Unspecified

Unspecified

100%

Unspecified

Unspecified

Cataract, dry eye, corneal toxicity (unspecified)

Bolek et al. [55]

1999

4

Unilateral

Low-grade (100%)

100%

12.6 (median)

0%

Ocular irritation, conjunctivitis, cataract (unspecified)

Dunbar et al. [56]

1990

10

8 unilateral; 1 bilateral

Unspecified

100%

29.5 (median)

0%

Epilation of eyelashes, erythema of the eyelid, conjunctival injection; excessive tearing (25%)

Erickson et al. [57]

1992

15

7 unilateral; 4 bilateral

EMZL (100%)

93%

Unspecified

Unspecified

 

Hasegawa et al. [58]

2003

9

Unilateral

EMZL (67%); DLBCL (11%); unspecified (22%)

100%

94 (median)

0%

Cataract (55.6%)

Jereb et al. [31]

1984

5

Unilateral

DWDL (60%); NWDL (20%); DPDL (20%)

100%

22 (median)

0%

Slight erythema and conjunctivitis in 1 patient

Kennerdell et al. [59]

1999

4

Unspecified

EMZL (100%)

100%

 

Unspecified

Mild xerophthalmia and chemosis (unspecified)

Kuhnt et al. [24]

2003

1

Unilateral

EMZL

100%

144

0%

Cataract

Lee, G-I et al. [60]

2018

121

37 unilateral; 42 bilateral

EMZL (100%)

100%

61.3 (median)

98%

Dry eye (26.6%); eye pain (5.1%); tearing (6.3%); cataract (6.3%)

Lee, S-w et al. [23]

2002

4

Unspecified

EMZL (100%)

100%

31 (median)

0%

Conjunctivitis (100%)

Liao et al. [61]

2002

12

Unspecified

Low-grade (83%), Intermediate-grade (17%)

100%

56.4 (mean)

0%

Lacrimal gland dysfunction (50%); cataract (25%)

Martinet et al. [62]

2003

34

22 unilateral; 6 bilateral

Low-grade (100%)

100%

55 (median)

0%

Inflammatory reaction; cataract (unspecified)

Matsuo et al. [63]

2004

6

4 unilateral; 2 bilateral

EMZL (100%)

100%

48 (median)

0%

Unspecified

Pelloski et al. [64]

2001

11

9 unilateral; 2 bilateral

SLL (91%); SLP (9%)

100%

87.5 (median)

0%

Cataract (18%); diabetic retinopathy (9%); epiphora (9%)

Shirota et al. [65]

2017

19

Unspecified

Unspecified

100%

32 (median)

0%

Cataract (unspecified)

Smitt & Donaldson [13]

1993

20

10 unilateral; 5 bilateral

DSC (45%); DWDL (25%); FM (20%); F + DSC (5%); ALH (5%)

Unspecified

44 (median)

6.7%

Mild conjunctival irritation (unspecified)

Stafford et al. [66]

2001

16

Unspecified

Unspecified

Unspecified

64.2 (median)

6.25%

 

Uno et al. [67]

2003

29

Unspecified

EMZL (100%)

100%

46 (median)

10%

Cataract, conjunctival irritation (unspecified)

Vitu et al. [68]

1991

19

9 unilateral; 5 bilateral

Unspecified

100%

Unspecified

7% (bilateral recurrence in patient with bilateral disease)

Cataract (31.6%)

Xicoy et al. [69]

2002

5

3 unilateral; 1 bilateral

EMZL (100%)

100%

50.5 (median)

0%

Conjunctivitis and epiphora (50%)

IFN-alpha

Blasi et al. [70]

2012

20

12 unilateral; 4 bilateral

EMZL (100%)

100%

65 (median)

15%

Temporary conjunctival chemosis and other ocular discomfort associated with injection; transient flu-like syndrome (100%)

Cellini et al. [71]

1996

1

Unilateral

EMZL

100%

12

0%

 

Holds et al. [72]

2012

2

Bilateral

EMZL (100%)

100%

27

0%

Mild discomfort associated with injections, transient loss of appetite

Lachapelle et al. [73]

2000

1

Unilateral

EMZL

100%

6

0%

Transient headaches and nausea; subconjunctival hemorrhage

Lucas et al. [74]

2003

2

Bilateral

Likely EMZL

100%

18

0%

 

Ross et al. [75]

2004

2

Bilateral

Unspecified

100%

12

0%

Injection discomfort, mild flu-like illness

Zayed et al. [76]

2013

1

Unilateral

EMZL

100%

10

0%

 

Zinzani et al. [77]

1997

4

Unilateral

EMZL (100%)

100%

32 (median)

0%

 

Zinzani et al. [78]

1999

4

Unspecified

EMZL (100%)

100%

47 (median)

0%

 

Rituximab

Crespo et al. [79]

2014

2

Bilateral

EMZL

100%

9

0%

Dry eye

Ferreri et al. [80]

2011

3

1 unilateral; 2 bilateral

EMZL (100%)

100%

11.5 (median)

0%

Ocular discomfort associated with injection (1 patient)

Rodriguez Villa et al. [81]

2017

1

Unilateral

FL

100%

10

0%

 

Antibiotic therapy

Abramson, Rollins, and Coleman [82] (PrevPak or Doxycycline)

2005

3

Unilateral

EMZL or unspecified low-grade (100%)

100%

21 (median)

0%

 

Danilko et al. [83] (Clarithromycin)

2013

1

Unilateral

EMZL

100%

0

0%

 

Ferreri et al. [84] (Doxycycline)

2006

14

Unspecified

EMZL (100%)

42.8%

Unspecified

21.4%

 

Govi et al. [85] (Clarithromycin)

2010

5

3 unilateral; 1 bilateral

EMZL (100%)

100%

27 (median)

0%

Unspecified

Grünberger et al. [86] (Doxycycline)

2006

5

1 unilateral; 2 bilateral

EMZL (100%)

0%

9 (median)

N/A

 

Höh et al. [87] (Doxycycline)

2016

1

Unilateral

EMZL

100%

60

0%

 
  1. CR= complete response; PR= partial response; EMZL= extra-nodal marginal zone lymphoma [low-grade]; FL= follicular lymphoma [low-grade]; DLBCL= diffuse large B-cell lymphoma [high-grade]; MCL= mantle cell lymphoma [high-grade]; DPDL= diffuse poorly differentiated; DWDL= diffuse well differentiated; NWDL= nodular well differentiated; DSC= diffuse small cleaved; FM= follicular mixed; ALH= atypical lymphoid hyperplasia; SLL= small lymphocytic lymphoma; SLP= small lymphocytic lymphoma; plasmacytoid